This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
KEYLearning Hub Optimising the care of your mNSCLC patients with KEYTRUDA plus chemotherapy KEYLearning Hub Optimising the care of your mNSCLC patients with KEYTRUDA plus chemotherapy

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Welcome to the KEYLearning Hub, a series of digestible peer-to-peer videos on the day-to-day management of patients with metastatic non-small cell lung cancer (mNSCLC) treated with KEYTRUDA® (pembrolizumab) plus chemotherapy.

Licensed indication

Listen to experienced clinical nurse specialists, oncologists, and specialist registrars share their real-world experience of patient management by discussing treatment journeys from initiation to end of treatment.

Here's what to expect from starting your KEYLearning journey...

Explore the hub...

Optimising patient care: hear from your peers

Learn how KEYTRUDA works and how to identify immune-mediated adverse events in KEYTRUDA plus chemotherapy patients

Coming soon: immune-related adverse events

Learn about the details and case studies for a range of immune-mediated adverse events in KEYTRUDA plus chemotherapy patients

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-02166 | Date of Preparation: July 2022